Lacosamide Medical Valley 100 mg Noruega - noruec - Statens legemiddelverk

lacosamide medical valley 100 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 100 mg

Lacosamide Medical Valley 50 mg Noruega - noruec - Statens legemiddelverk

lacosamide medical valley 50 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 50 mg

Lacosamide Medical Valley 150 mg Noruega - noruec - Statens legemiddelverk

lacosamide medical valley 150 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 150 mg

Lacosamide Medical Valley 200 mg Noruega - noruec - Statens legemiddelverk

lacosamide medical valley 200 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 200 mg

Slinda 4 mg Noruega - noruec - Statens legemiddelverk

slinda 4 mg

exeltis healthcare s.l. (1) - drospirenon - tablett, filmdrasjert - 4 mg

Tibsovo Unió Europea - noruec - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Lacosamide Adroiq Unió Europea - noruec - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lakosamid - epilepsi - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Reyataz 300 mg Noruega - noruec - Statens legemiddelverk

reyataz 300 mg

orifarm as - atazanavirsulfat - kapsel, hard - 300 mg

Exalief Unió Europea - noruec - EMA (European Medicines Agency)

exalief

bial - portela ca, s.a. - eslikarbazepinacetat - epilepsi - antiepileptics, - exalief er angitt som tilleggsbehandling behandling hos voksne med delvis-utbruddet anfall med eller uten sekundær generalisering.

Stocrin 600 mg Noruega - noruec - Statens legemiddelverk

stocrin 600 mg

orifarm as - efavirenz - tablett, filmdrasjert - 600 mg